CTLA4 and pneumonitis: Pneumonitis occurs in approximately 5% of patients receiving ICI therapy, can be life-threatening [33,34,35,36], and is less common in monotherapy with anti-PD-1/PD-L1 antibodies (3%) compared to combination therapy with anti-CTLA-4 antibodies (10%) [35].